Education
About Us
Working with TipRanks
Follow Us
Provectus Pharmaceuticals (PVCT)
:PVCT
Total Valuation
Provectus Pharmaceuticals has a market cap or net worth of $27.28M. The enterprise value is ―.
Market Cap$27.28M
Enterprise Value―
Share Statistics
Provectus Pharmaceuticals has 420,279,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding420,279,880
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Provectus Pharmaceuticals’s return on equity (ROE) is 0.79 and return on invested capital (ROIC) is 141.75%.
Return on Equity (ROE)0.79
Return on Assets (ROA)-4.70
Return on Invested Capital (ROIC)141.75%
Return on Capital Employed (ROCE)0.66
Revenue Per Employee102.86K
Profits Per Employee-793.69K
Employee Count6
Asset Turnover0.61
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Provectus Pharmaceuticals is ―. Provectus Pharmaceuticals’s PEG ratio is -0.20.
PE Ratio―
PS Ratio81.70
PB Ratio-8.46
Price to Fair Value-8.46
Price to FCF-15.35
Price to Operating Cash Flow-8.40
PEG Ratio-0.20
Income Statement
In the last 12 months, Provectus Pharmaceuticals had revenue of 617.14K and earned -4.73M in profits. Earnings per share was -0.01.
Revenue617.14K
Gross Profit609.98K
Operating Income-3.95M
Pretax Income-4.77M
Net Income-4.73M
EBITDA-4.53M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -3.37M and capital expenditures 0.00, giving a free cash flow of -3.37M billion.
Operating Cash Flow-3.37M
Free Cash Flow-3.37M
Free Cash Flow per Share>-0.01
Dividends & Yields
Provectus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.38
52-Week Price Change-45.45%
50-Day Moving Average0.07
200-Day Moving Average0.08
Relative Strength Index (RSI)24.56
Average Volume (3m)223.48K
Important Dates
Provectus Pharmaceuticals upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Provectus Pharmaceuticals as a current ratio of 0.14, with Debt / Equity ratio of -42.83%
Current Ratio0.14
Quick Ratio0.14
Debt to Market Cap0.06
Net Debt to EBITDA-0.64
Interest Coverage Ratio-16.54
Taxes
In the past 12 months, Provectus Pharmaceuticals has paid -9.32K in taxes.
Income Tax-9.32K
Effective Tax Rate<0.01
Enterprise Valuation
Provectus Pharmaceuticals EV to EBITDA ratio is -11.78, with an EV/FCF ratio of -16.23.
EV to Sales86.36
EV to EBITDA-11.78
EV to Free Cash Flow-16.23
EV to Operating Cash Flow-16.23
Balance Sheet
Provectus Pharmaceuticals has $72.48K in cash and marketable securities with $3.57M in debt, giving a net cash position of -$3.50M billion.
Cash & Marketable Securities$72.48K
Total Debt$3.57M
Net Cash-$3.50M
Net Cash Per Share>-$0.01
Tangible Book Value Per Share-$0.01
Margins
Gross margin is 16.59%, with operating margin of -640.81%, and net profit margin of -766.92%.
Gross Margin16.59%
Operating Margin-640.81%
Pretax Margin-773.13%
Net Profit Margin-766.92%
EBITDA Margin-733.22%
EBIT Margin-734.36%
Analyst Forecast
The average price target for Provectus Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―